Neurogenic cardiovascular disorders in α-synucleinopathies: diagnostic and therapy issues

Diagnostics and treatment of the neurogenic cardiovascular disorders in α-synucleinopathies are difficult due to the early-onset of autonomic deficiency and masking under other diseases. The paper discusses the development and progression mechanisms of manifestations of neurogenic cardiovascular pathology. The main forms include neurogenic orthostatic hypotension, neurogenic hypertension in supine position (recumbent neurogenic hypertension) and its nocturnal variant. The existing and promising diagnostic approaches and related difficulties are presented. The possible relationship of cardiovascular disorders in α-synucleinopathies and their manifestations is shown. A possible diagnostic algorithm and possible non-drug and drug treatment and prevention approaches in neurogenic cardiovascular deficiency in α-synucleinopathies are presented. The importance of a multidisciplinary approach is emphasized.

1. Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, Sosa-Ortiz AL, Illigens BMW et al. Autonomic dysfunction in α-synucleinopathies. Front Neurol. 2019;10:363. doi:10.3389/fneur.2019.00363

2. Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018;33(3):349–358. doi:10.1002/mds.27186

3. Goedert M, Jakes R, Spillantini MG. The synucleinopathies: twenty years on. J Parkinsons Dis. 2017;7(s1): S 51–S69. doi:10.3233/JPD‑179005

4. Peelaerts W, Baekelandt V. a-Synuclein strains and the variable pathologies of synucleinopathies. J Neurochem. 2016;139(Suppl. 1):256–274. doi:10.1111/jnc.13595

5. Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and biomarkers. J. Neural Transm. 2016;123(6):555–572. doi:10.1007/s00702-016-1545-2

6. Brown TP. Pure autonomic failure. Pract Neurol. 2017;17(5):341–348. doi:10.1136/practneurol‑2016-001559

7. Arai K, Kato N, Kashiwado K, Hattori T. Pure autonomic failure in association with human alpha-synucleinopathy. Neurosci Lett. 2000;296(2–3):171–173. doi:10.1016/s0304-3940(00)01623-2

8. Palma J-A, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298–308. doi:10.1002/mdc3.12478

9. Litvinenko IV, Odinak MM, Shatova AV, Sologub OS. The structure of cognitive disorders at different stages of Parkinson’s disease. Vestnik Rossiiskoj VoennoMeditsinskoij Akademii = Bulletin of the Military Medical Academy. 2007;3(19):43–49. In Russian

10. Espay AJ, LeWitt PA, Hauser RA, Masellis M, Lang AE. Neurogenic orthostatic hypotension and supine hypertension in Parkinson’s disease and related synucleinopathies: prioritisation of treatment targets. Lancet Neurol. 2016;15(9):954–966. doi:10.1016/S1474-4422(16)30079-5

11. Low PA, Tomalia VA. Orthostatic hypotension: mechanisms, causes, management. J Clin Neurol. 2015,11(3):220–226. doi:10.3988/jcn.2015.11.3.220

12. Turusheva A.V., Kotovskaya Yu.V., Frolova E.V. Association between heart rate response during orthostatic test and falls in polymorbid patients aged 60 years and older. Arterial’naya Gipertenziya = Arterial Hypertension. 2019;25(4):433–441. doi:0.18705/1607-419X‑2019-25-4-433-441. In Russian.

13. Jones PK, Shaw BH, Raj SR. Orthostatic hypotension: managing a difficult problem. Exp Rev Cardiovasc Ther. 2015;13(11):1263–1276. doi:10.1586/14779072.2015.1095090

14. Norcliffe-Kaufmann L, Kaufmann H, Palma J-A. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol. 2018;83(3):522–531. doi:10.1002/ana.25170

15. Palma J-A. Autonomic dysfunction in Parkinson’s disease and other synucleinopathies: introduction to the series. Mov Disord. 2018:33(3):347–348. doi:10.1002/mds.27347

16. Ma LY, Liu GL, Wang DX, Zhang MM, Kou W-Y, Feng T. Alpha-Synuclein in peripheral tissues in Parkinson’s Disease. ACS Chem Neurosci. 2019;10(2):812–823. doi:10.1021/acschemneuro.8b00383

17. Donadio V, Incensi A, Rizzo G, Capellari S, Pantieri R, Maserati MS et al. A new potential biomarker for dementia with Lewy bodies: Skin nerve α-synuclein deposits. J Neurol. 2017;89(4):318–326. doi:10.1212/WNL.0000000000004146

18. Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis. 2012;46(3):572–580.

19. Guyenet PG, Koshiya N, Huangfu D, Verberne AJ, Riley TA. Central respiratory control of A5 and A6 pontine noradrenergic neurons. Am J Physiol. 1993;264(6 Pt 2):1035–1044. doi:10.1152/ajpregu.1993.264.6.R1035

20. Deguchi K, Sasaki I, Touge T, Tsukaguchi M, Takeuchi H, Kuriyama S. Abnormal baroreceptor-mediated vasopressin release as possible marker in early diagnosis of multiple system atrophy. J Neurol Neurosurg Psychiatry. 2004;75(1):110–115.

21. Duffin J, Sobczyk O, McKetton L, Crawley A, Poublanc J, Venkatraghavan L et al. Cerebrovascular resistance: the basis of cerebrovascular reactivity. Front Neurosci. 2018;12:409. doi:10.3389/fnins.2018.00409. PMID: 29973862; PMCID: PMC6020782

22. Robertson AD, Messner MA, Shirzadi Z, Kleiner-Fisman G, Lee J, Hopyan J et al. Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. Parkinsonism Relat Disord. 2016;22:80–86. doi:10.1016/j.parkreldis.2015.11.019

23. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat. Disord. 2011;17(10):724–729. doi:10.1016/j.parkreldis.2011.04.016

24. Kirtaev SYu. Autonomic disorders in Parkinson’s disease. PhD Thesis. SPb., 2004. 22 p. In Russian.

25. Litvinenko IV, Dynin PS, Trufanov AG, Gimadutdinov RF, Maltsev DS. Eye as an object of investigation of cognitive impairment in Parkinson’s disease. Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova. 2018;118(6–2):105–114. doi:10.17116/jnevro2018118062105. In Russian.

26. Haubrich C, Pies K, Dafotakis M, Block F, Kloetzsch C, Diehl RR. Transcranial doppler monitoring in Parkinson’s disease: cerebrovascular compensation of orthostatic hypotension. Ultrasound Med Biol. 2010;36(10):1581–1587. doi:10.1016/j.ultrasmedbio.2010.06.016

27. Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS): Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355–362. doi:10.1007/s10286-018-0529-8

28. Di Stefano C, Maule S. Treatment of supine hypertension in autonomic failure: a case series. Clin Auton Res. 2018;28(2):245–246. doi:10.1007/s10286-017-0479-6

29. Chisholm P, Anpalahan M. Orthostatic hypotension: pathophysiology, assessment, treatment and the paradox of supine hypertension. Intern Med J. 2017;47(4):370–379. doi:10.1111/imj.13171

30. Palma J-A, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015;30(5):639–645. doi:10.1002/mds.26079

31. The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Movement disorder society task force on rating scales for Parkinson’s Disease. Mov Disord. 2003; 18(7):738–750.

32. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. doi:10.1212/WNL.0000000000004058

33. Peters R, Anstey KJ, Booth A, Beckett N, Warwick J, Antikainen R et al. Orthostatic hypotension and symptomatic subclinical orthostatic hypotension increase risk of cognitive impairment: an integrated evidence review and analysis of a large older adult hypertensive cohort. Eur Heart J 2018;39(33):3135–3143. doi:10.1093/eurheartj/ehy418

34. Bugalho P, Mendonça M, Lampreia T, Miguel R, Barbosa R, Salavisa M. Heart rate variability in Parkinson disease and idiopathic REM sleep behavior disorder. Clin Auton Res. 2018;28(6):557–564. doi:10.1007/s10286-018-0557-4

35. Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord. 2009;24(Suppl. 2):732–741. doi:10.1002/mds.22499

36. Jacobson AF, White S, Travin MI, Tseng C. Impact of concomitant medication use on myocardial 123I-mIBG imaging results in patients with heart failure. Nucl Med Commun. 2017;38(2):141–148. doi:10.1097/MNM.0000000000000619

37. Litvinenko IV, Andreev RV, Dynin PS, Istomin VV. A case of acute hyponatremia simulating akinetic crisis in a Parkinson’s disease patient. Nevrologicheskiy Zhurnal = Neurological Journal. 2016;21(3):168–172. doi:10.18821/1560-9545-2016-21-3-168-172. In Russian.

38. Quarracino C, Otero-Losada M, Capani F, Pérez-Lloret S. State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson’s disease. Expert Opin Pharmacother. 2020;21(4):445–457. doi:10.1080/14656566.2020.1713097

39. Palma JA, Kaufmann H. Orthostatic hypotension in Parkinson Disease. Clin Geriatr Med. 2020;36(1):53–67. doi:10.1016/j.cger.2019.09.002